<DOC>
	<DOCNO>NCT01615185</DOCNO>
	<brief_summary>Background : Surveys show antipsychotic drug combination frequently prescribe . Amisulpride , atypical antipsychotic agent , low incidence extrapyramidal symptom ( EPS ) high cost compare sulpiride . The objective study compare efficacy safety 800-mg/d amisulpride 400-mg/d amisulpride plus 800-mg sulpiride treatment acute psychotic exacerbation schizophrenia . Method : In 6-week , double-blind , fixed-dose study , patient schizophrenia randomly assign amisulpride ( 800 mg/d ) amisulpride ( 400 mg/d ) plus sulpiride ( 800 mg/d ) .The hypothesis two treatment group similar efficacy safety , different cost .</brief_summary>
	<brief_title>A Randomized , Double-blind , Comparison Efficacy Safety Amisulpride Versus Low-dose Amisulpride Plus Low-dose Sulpiride Treatment Schizophrenia</brief_title>
	<detailed_description>Background : Antipsychotic monotherapy recognize treatment choice patient schizophrenia . Surveys show antipsychotic drug combination frequently prescribe , yet clinical study examine practice . Amisulpride , atypical antipsychotic agent , low incidence extrapyramidal symptom ( EPS ) high cost compare sulpiride . It report mean dos low-potency typical antipsychotic le 600 mg/day chlorpromazine equivalent dose high risk EPS atypical antipsychotic . The objective study compare efficacy safety 800-mg/d amisulpride 400-mg/d amisulpride plus 800-mg sulpiride treatment acute psychotic exacerbation schizophrenia . Method : In 6-week , double-blind , fixed-dose study , patient schizophrenia ( DSM-IV diagnosis ) randomly assign amisulpride ( 800 mg/d ) amisulpride ( 400 mg/d ) plus sulpiride ( 800 mg/d ) . The hypothesis two treatment group similar efficacy safety , different cost . The efficacy assessment change baseline score Clinical Global Impression-Severity ( CGI-S ) , Positive Negative Syndrome Scale ( PANSS ) subscales ( positive scale , negative scale , general psychopathology scale ) , Calgary Depression Scale Schizophrenia ( CDSS ) , Global Assessment Functioning ( GAF ) . Safety assessment include change baseline Simpson-Angus Rating Scale ( SAS ) , Abnormal Involuntary Movement Scale ( AIMS ) , Barnes Akathisia Scale ( BAS ) , UKU Side-effects Rating Scale ( UKU ) , change baseline prolactin level , body weight , vital sign , blood pressure , AC glucose level , lipid profile ( cholesterol , high density lipid protein [ HDL ] , low density lipid protein [ LDL ] , triglyceride [ TG ] ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Sulpiride</mesh_term>
	<mesh_term>Sultopride</mesh_term>
	<criteria>schizophrenia CGI &gt; =4 washout antipsychotic least 35 day write informed consent History serious adverse event sulpiride amisulpride History neuroleptic malignant syndrome tardive dyskinesia antipsychotic treatmentresistant schizophrenia longacting antipsychotic past 3 month comorbid substance abuse/dependence female subject pregnancy severe physical illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>schizophrenia</keyword>
	<keyword>amisulpride</keyword>
	<keyword>sulpiride</keyword>
	<keyword>antipsychotic combination</keyword>
</DOC>